PaulMookencherryThambiMD

Oncology • Weston, FL

Vice Chairman, Institutional Review Board, Shady Grove Adventist Hospital

Join to view full profile

Dr. Thambi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thambi's full profile

Already have an account?

Office
2950 Cleveland Clinic Blvd
Weston, FL 33331
Phone+1 877-463-2010

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003
Rush University Medical CenterResidency, Internal Medicine, 1996 - 1999
Ohio State University College of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2024 - 2026
MD State Medical License 2003 - 2025
IL State Medical License 1996 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2, Phase 3
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

15 citations
Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
Manish Agrawal, William Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli
Cancer. 2024-04-01
3 citations
Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.
Yvan Beaussant, Elise Tarbi, Kabir Nigam, Skye Miner, Zachary Sager
Cancer. 2024-04-01
1 citations
Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.
Robert Gramling, Emily Bennett, Keith Curtis, William Richards, Donna M Rizzo
Journal of Palliative Medicine. 2023-12-01

Press Mentions

Sunstone Therapies to Present Data on the Long-Term Efficacy of Psilocybin Therapy in Cancer Patients with Major Depressive Disorder (MDD) at the ASCO 2023 Annual MeetingMay 11th, 2023
Sunstone Therapies Collaborates with MAPS to Conduct Clinical Trial of MDMA-Assisted Therapy for PTSDSeptember 14th, 2022
First Clinical Trial Launched to Test Psilocybin Therapy for Depression in Cancer PatientsSeptember 16th, 2020
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member